Mohammadi Mohsen, Yazdanparast Razieh
Institute of Biochemistry and Biophysics, University of Tehran, P. O. Box 13145-1384, Tehran, Iran.
Exp Toxicol Pathol. 2010 Sep;62(5):533-8. doi: 10.1016/j.etp.2009.07.002. Epub 2009 Jul 28.
The antioxidant activity of [N, N'-Bis (salicylidene) ethane-1, 2-diaminato] oxovanadium (IV) complex (VO-salen complex) was evaluated using different in vitro evaluating systems including superoxide anion (O(2)(-)) and hydrogen peroxide (H(2)O(2)) scavenging activities. In addition, the inhibitory effects of this compound on protein oxidation and inhibition of Fe(2+)/ascorbate-induced lipid peroxidation were studied using rat liver homogenate. In vitro results revealed that the VO-salen complex has strong inhibitory effects on protein oxidation and lipid peroxidation of the liver homogenate along with a concentration-dependent quenching of H(2)O(2) and O(2)(-) radicals. In an in vivo approach, hepatoprotective potential of the VO-salen complex against liver damages induced by CCl(4) treatment was also investigated. After intraperitoneal injection of CCl(4) to rats, various biochemical changes associated with liver injury and/or oxidative stress were measured. The results showed that the sera levels of ALT, AST, ALP and the content of hepatic thiobarbituric acid reactive substances (TBARS) were all increased and the glutathione (GSH) content and the hepatic superoxide dismutase (SOD) and catalase (CAT) activities were decreased in CCl(4)-treated rats. However, simultaneous treatment of rats with VO-salen (0.6 mg/kg) and CCl(4) significantly attenuated the sera levels of ALT, AST, ALP and the hepatic TBARS content. In addition, by VO-salen therapy, the hepatic SOD and CAT activities and the GSH content were all restored back almost to their normal levels. The liver damages were also significantly ameliorated as compared to the CCl(4)-treated rats. Based on these results, the VO-salen complex might be considered as an effective antioxidant and hepatoprotective agent suitable for further biological evaluation.
使用包括超氧阴离子(O₂⁻)和过氧化氢(H₂O₂)清除活性在内的不同体外评估系统,评估了[N,N'-双(水杨醛)乙烷-1,2-二氨基]氧钒(IV)配合物(VO-萨伦配合物)的抗氧化活性。此外,使用大鼠肝脏匀浆研究了该化合物对蛋白质氧化的抑制作用以及对Fe²⁺/抗坏血酸诱导的脂质过氧化的抑制作用。体外实验结果表明,VO-萨伦配合物对肝脏匀浆的蛋白质氧化和脂质过氧化具有强烈的抑制作用,同时对H₂O₂和O₂⁻自由基具有浓度依赖性的淬灭作用。在体内实验中,还研究了VO-萨伦配合物对四氯化碳处理诱导的肝损伤的肝保护潜力。给大鼠腹腔注射四氯化碳后,测量了与肝损伤和/或氧化应激相关的各种生化变化。结果表明,四氯化碳处理的大鼠血清中谷丙转氨酶(ALT)、谷草转氨酶(AST)、碱性磷酸酶(ALP)水平以及肝组织中硫代巴比妥酸反应性物质(TBARS)含量均升高,而谷胱甘肽(GSH)含量以及肝脏中超氧化物歧化酶(SOD)和过氧化氢酶(CAT)活性均降低。然而,同时用VO-萨伦(0.6 mg/kg)和四氯化碳处理大鼠,可显著降低血清中ALT、AST、ALP水平以及肝脏中TBARS含量。此外,通过VO-萨伦治疗,肝脏中SOD和CAT活性以及GSH含量均几乎恢复到正常水平。与四氯化碳处理的大鼠相比,肝脏损伤也得到了显著改善。基于这些结果,VO-萨伦配合物可被视为一种有效的抗氧化剂和肝保护剂,适合进一步的生物学评估。